Erythema Migrans | Cytokines and Chemokines in Erythema Migrans

Erythema Migrans research study

What is the primary objective of this study?

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Who is eligible to participate?

Inclusion Criteria: - erythema migrans in patients > 18 years Exclusion Criteria: - pregnancy or lactation - taking antibiotic with antiborrelial activity within 10 days

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Erythema Migrans

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:antibiotic treatmentPatient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

erythema migrans patients treated with antibioticsadult patients with erythema migrans will be treated with oral antibiotics

Study Status


Start Date: July 2013

Completed Date: December 31, 2020

Phase: N/A

Type: Interventional


Primary Outcome: inflammatory proteins in erythema migrans patients

Secondary Outcome: gene polymorphisms in erythema migrans patients

Study sponsors, principal investigator, and references

Principal Investigator: Franc Strle, MD, PhD

Lead Sponsor: University Medical Centre Ljubljana

Collaborator: University of Ljubljana School of Medicine, Slovenia

More information:

Discuss Erythema